The peptide manufacturing sector entered its largest capacity buildout in two decades as the GLP-1 wave overwhelmed legacy solid-phase synthesis capacity. Bachem, the Swiss peptide CDMO that supplies a significant share of GLP-1 API for both Novo Nordisk and Eli Lilly, expanded its US footprint through a strategic partnership and asset acquisition (April 23, 2026). CordenPharma's $200M+ Swiss greenfield GMP plant opened in early 2025 and was followed by the May 2026 acquisition of AmbioPharm — the US-China peptide CDMO whose June 16 announcement of a $118.96M Aiken County, South Carolina expansion (200+ jobs) puts large-scale US-based peptide API capacity on a five-year ramp. PolyPeptide guided to 20-25% revenue growth at constant currency for 2026 with EBITDA margins in the mid- to high-teens range.
Manufacturing quality has moved from an industry-internal concern to a regulatory pressure point. The EMA's first-ever dedicated synthetic peptide guideline (EMA/CHMP/CVMP/QWP/367182/2025) entered into force June 1, 2026, covering peptide-specific impurity types, manufacturing routes, pooling strategy, and comparability for both human and veterinary APIs. On the US side, the Camurus Oclaiz second Complete Response Letter (June 10, 2026) was tied entirely to unresolved cGMP observations at a third-party manufacturer — the second time the same inspection has blocked a peptide approval — illustrating how manufacturing readiness can gate even a successful clinical program. The TIDES USA conference each May has become the peptide industry's primary capacity-and-supply-chain forum.
Stories here cover CDMO consolidation, GMP enforcement, capacity expansion, and the manufacturing economics that determine how quickly the next-generation peptide pipeline reaches commercial scale. See [[cordenpharma]], [[ambiopharm]], [[bachem]], and [[polypeptide]] for adjacent threads.
Bachem AG (SIX: BANB) announced May 25, 2026 that Chief Commercial Officer Torsten Wöhr decided to pursue a new opportunity outside the company. CEO Anne-Kathrin Stoller — who succeeded Thomas Meier as CEO on January 1, 2026 after 19 years at Bachem in increasingly senior roles (Head of Business Development & Sales Europe, Chief Marketing Officer, COO Americas) — assumed the CCO role in addition to her CEO responsibilities until a successor is appointed. Bachem is one of two major peptide CDMOs supplying the global GLP-1 API market alongside PolyPeptide; the company is in the middle of multi-site capacity expansion across Switzerland (Bubendorf Module I completion H1 2026) and the US (San Diego, King of Prussia). The CCO transition follows months of senior turnover and comes as GLP-1 manufacturing capacity has become the rate-limiting constraint for the entire commercial peptide industry.
The European Medicines Agency's first-ever dedicated 'Guideline on the Development and Manufacture of Synthetic Peptides' (EMA/CHMP/CVMP/QWP/367182/2025) entered into force June 1, 2026 after adoption by CHMP on December 1, 2025 and CVMP on December 4, 2025. The guideline applies to both new and existing synthetic peptide active substances used in human and veterinary medicines, including investigational medicinal products and post-authorisation changes, and covers manufacturing routes, peptide-specific impurity types, pooling strategy in preparative chromatography, comparability requirements, characterization, specifications, and analytical control. Biological peptides produced by recombinant technology and radiopharmaceuticals are excluded. The standard arrives on the same regulatory calendar as the FDA's PCAC peptide reclassification review (July 23-24, 2026) and the FDA's 503B GLP-1 bulks exclusion comment window (closes June 29).
Camurus said on June 10 that the FDA had issued a Complete Response Letter on the Oclaiz (CAM2029) NDA, the second the program has received and the second based solely on unresolved observations from a September 2024 cGMP inspection at a third-party contract manufacturer. The CRL did not cite clinical efficacy or safety. Camurus expects to resubmit in Q4 2026 with a second validated manufacturer; an approval pushed to the first half of 2027 leaves the US launch about a year behind the EU and UK rollouts (under the Oczyesa brand) that landed in 2025.
TIDES USA 2026 — the year's leading oligo, peptide, and mRNA therapeutics conference — opens May 11–14 in Boston, with six concurrent scientific tracks and 200+ presentations. Programmatic highlights include CMC strategy for complex dual and triple agonists under regulatory scrutiny, defining defensible starting materials for GLP-1 APIs, and how CDMOs are securing scarce GMP suite capacity dominated by big-pharma volume contracts. Bachem, PolyPeptide, CordenPharma, Gilead, and Novo Nordisk teams are scheduled to speak — the same week as Hims & Hers' Q1 print and within the new AJMC oral-peptides public-facing news cycle.
Swiss peptide CDMO Bachem announced a strategic partnership and asset acquisition in April 2026 to scale large-scale peptide API production. The move responds to surging demand for GLP-1 and next-generation peptide drugs — the global peptide synthesis market is now projected to reach $2.26 billion by 2033 at an 11.4% CAGR. Bachem previously secured a CHF 1 billion peptide supply contract and is operating three site expansions to address capacity constraints that have periodically disrupted semaglutide and tirzepatide supply.